Status:
RECRUITING
68Ga-PSMA PET in the Renal Cell Carcinoma
Lead Sponsor:
Xijing Hospital
Collaborating Sponsors:
Air Force Military Medical University, China
Shaanxi Provincial People's Hospital
Conditions:
Renal Cancer
Metastases
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced C...
Eligibility Criteria
Inclusion Criteria:
- 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
- In contrast-enhanced CT staging, suspicious metastases were found;
- There were no known peripheral or central venous problems;
- 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
- Signed the informed consent form of voluntary participation in clinical trials.
Exclusion Criteria:
- Age ≤ 18 years old;
- Can't stand lying flat in PET / CT examination;
- There are contraindications for 68Ga PSMA ligands;
- In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
- Renal function is impaired or hemodialysis is in progress.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04987086
Start Date
June 1 2021
End Date
December 1 2027
Last Update
March 11 2026
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
2
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
3
Qinghai University Affiliated Hospital
Xining, Qinghai, China
4
Xijing Hospital
Xi'an, Shaan'xi, China, 710032